Prolongation of the latency period in preterm premature rupture of the membranes using prophylactic antibiotics and tocolysis.
Mixed results have been obtained in several studies using tocolysis or antibiotics individually in the treatment of premature rupture of membranes (PROM). We compared the outcomes of a management protocol consisting of tocolysis, prophylactic antibiotic administration, and documentation of pulmonary maturity with a control group treated with passive expectant management for premature rupture of membranes. There were 55 women in the treatment group and 57 women in the control group. The mean latent phase (+/- SEM) in the treatment group was 7.34 (+/- 1.25) days compared with 1.86 (+/- .431) days in the control group (P less than .001). Eighteen of 55 patients (33%) in the treatment group were electively delivered after documentation of lung maturity, contributing to a falsely lowered mean latent phase in the treatment group. Twenty-four patients in the treatment group and 6 in the control group had a latent phase of 5 days or greater (P = .00018). There were 9 postpartum infections in the control group and 10 infections in the treatment group (P = NS). There was no difference in the length of latent phase of patients treated with ceftizoxime compared with the other antibiotics used (cefoxitin, cefazolin, ampicillin), although postpartum ceftizoxime was more effective in preventing postpartum infections (1 of 28 vs 9 of 27) (P = .005). There were fewer infected neonates in the study group, but this was not significant. It appears that treatment with this protocol significantly prolongs the latent phase in patients with preterm PROM without increasing infectious morbidity.
Fortunato
S J
SJ
Department of Obstetrics and Gynecology, East Tennessee State University, Johnson City 37614.
Welt
S I
SI
Eggleston
M
M
Cole
J
J
Bryant
E C
EC
Dodson
M G
MG
D000328:Adult; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000151:congenital; D002437:Cefazolin / Q000627:therapeutic use; D002440:Cefoxitin / Q000627:therapeutic use; D015296:Ceftizoxime / Q000627:therapeutic use; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000628:therapy*; D005323:Fetal Monitoring; D005325:Fetal Organ Maturity; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000196:embryology; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D011247:Pregnancy; D011645:Puerperal Infection / Q000517:prevention & control; D012189:Retrospective Studies; D015145:Tocolysis / Q000379:methods; D014590:Uterine Contraction
D000900:Anti-Bacterial Agents; D002440:Cefoxitin; D000667:Ampicillin; D015296:Ceftizoxime; D002437:Cefazolin